Home / Business and Economy / Moderna's Q1 Revenue Surges Past Estimates
Moderna's Q1 Revenue Surges Past Estimates
1 May
Summary
- Moderna's Q1 revenue exceeded estimates, driven by international vaccine sales.
- Company is expanding beyond COVID vaccines into flu, norovirus, and cancer therapies.
- Moderna anticipates a more stable US COVID market by 2026.
Moderna reported first-quarter revenue of $389 million, surpassing analyst expectations of $228 million. This growth was primarily fueled by better-than-expected international sales of its COVID-19 vaccine, which amounted to $311 million compared to $78 million in U.S. markets.
The company is strategically expanding its focus beyond infectious diseases as demand for COVID vaccines lessens post-pandemic. Key developments are anticipated for its mRNA-based flu vaccine, with a decision date from the FDA set for August 5. Furthermore, late-stage data is expected for a norovirus vaccine and an individualized cancer vaccine developed with Merck.
Moderna anticipates a more stable U.S. COVID market by 2026. The company reiterated its 2026 forecast for revenue growth of up to 10% year-over-year. However, the quarter also included a net loss per share of $3.40, partly due to charges from a patent dispute settlement.
